Gary Collins
Cardiovascular Disease · Little Rock, ARNPI 1558319962
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,712 of the $8,106 with a category attached, or 70.5%. It is spread thinly across 30 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2019 at $4,741 and has fallen 99.5% since, to $24 in 2025.
Across 372 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Johnson & Johnson$1K
- Novartis$935
- E.r. Squibb & Sons, L.L.C.$739
- Amgen$632
- Abiomed$565
- plus $2K from 24 others
What the payments were for
- Consulting fees$5006%
- Speaking & faculty fees$1,75022%
- Food & beverage$5,71270%
- Education$1452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $1,876 |
| Johnson & Johnson | 79 | $1,038 |
| Novartis | 81 | $935 |
| E.r. Squibb & Sons, L.L.C. | 26 | $739 |
| Amgen | 47 | $632 |
| Abiomed | 10 | $565 |
| Boston Scientific | 16 | $493 |
| Boehringer Ingelheim | 9 | $240 |
| AstraZeneca(2 entities) | 15 | $226 |
| Abbott | 7 | $202 |
| Sanofi-aventis U.S. LLC | 11 | $144 |
| Merck | 10 | $133 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $118 |
| Astellas Pharma US Inc | 2 | $104 |
| Amarin Pharma, Inc. | 7 | $103 |
| Alnylam Pharmaceuticals Inc. | 5 | $96 |
| Philips North America LLC | 4 | $82 |
| Asahi Intecc USA, Inc. | 1 | $76 |
| Portola Pharmaceuticals, LLC | 3 | $62 |
| Actelion Pharmaceuticals US, Inc. | 4 | $55 |
| Lundbeck LLC | 3 | $53 |
| Cardiva Medical, Inc. | 1 | $27 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Biotronik Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Gilead | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$2,250
- Impella$378
- JARDIANCE$118
- GENERAL - THERAPIES$117
- XARELTO$112
- ENTRESTO$107
- ROTABLATOR$101
How this compares
$8,106 in reported general payments places this provider in the 75th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.